Healing the syk through kinase inhibitors

New England Journal of Medicine

Volumn 363, Issue 14, 2010, Pages 1362-1364

  Rivera, Juan ^a   Colbert, Robert A ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FC RECEPTOR; HYDROXYCHLOROQUINE; IMATINIB; INTERLEUKIN 1; JANUS KINASE 3 INHIBITOR; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; R 788; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; FOSTAMATINIB; OXAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; SIGNAL PEPTIDE;

B LYMPHOCYTE; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; EDITORIAL; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; JOINT DESTRUCTION; NATURAL KILLER CELL; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; RHEUMATOID ARTHRITIS; SYNOVITIS; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; PHYSIOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OXAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES;

EID: 77957344572     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1006527     Document Type: Editorial

References (11)

1. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
2. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009;5:531-41.
3. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:3309-18.
4. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-12.
5. Cha HS, Boyle DL, Inoue T, et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006;317:571-8.
6. Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today 2000;21:148-54. (Pubitemid 30122705)
7. Mócsai A, Humphrey MB, Van Ziffle JA, et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A 2004;101:6158-63. (Pubitemid 38520544)
8. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315:971-9.
9. Clemens GR, Schroeder RE, Magness SH, et al. Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth Defects Res A Clin Mol Teratol 2009;85:130-6.
10. Coopman PJ, Do MT, Barth M, et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000;406:742-7.
11. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2010;69:413-6.